NEW YORK, NY--(Marketwire -02/20/12)- Pharmaceutical stocks have underperformed the broader market in the early stages of 2012. The iShares Dow Jones U.S. Pharmaceuticals Index Fund (IHE) -- which measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines -- is trailing the Dow Jones industrial average by more than 30 percent year-to-date, as major drug manufacturers continue to cope with patent expirations making way for a rise in generic competition. Five Star Equities examines the outlook for companies in the Drug Manufacturers - Major Industry and provides equity research on Eli Lilly & Company (NYSE: LLY - News) and AstraZeneca Plc (NYSE: AZN - News) (LSE: AZN - News). Access to the full company reports can be found at:
To offset the loss in revenues as a result of generic competition, several drug manufacturers have turned to employee layoffs to cut costs. According to a recent survey from PharmaIQ, roughly 44 percent of pharmaceutical employees are fearful they will lose their jobs. Approximately half of the surveyed company executives said they're expecting staffing levels to stay the same for now. Although nearly 32 percent of those surveyed expect their departments to lose employees, a mere 19 percent expect their staffs to grow in the near term.
Five Star Equities releases regular market updates on the Drug Manufacturers - Major industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.
As reported in Fierce Pharma, many of the recent job cuts have been "laid at the foot of generic competition." As no big sales forces are necessary to sell drugs that have or soon will lose patent protection, for example.
Earlier this month the U.S. FDA proposed guidelines for approving the first lower-cost copies of biologic drugs derived from living cells. While low-cost copies of biotech drugs are used in Europe, none has yet been approved in the U.S. The law requires the FDA to establish a review process for the treatments that may save public health programs like Medicare about $7 billion in a decade, according to the Congressional Budget Office.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: